Last updated: January 28, 2026
Summary
QBREXZA (glycopyrronium cloth) is a topical prescription treatment for primary axillary hyperhidrosis (excessive underarm sweating). Its development was led by Dermira, Inc., later acquired by Eli Lilly and Company in 2020. This report reviews recent clinical trial developments, evaluates the current market landscape, and projects future growth trends for QBREXZA through 2030.
1. Clinical Trials Update for QBREXZA
a. Overview of Clinical Development
QBREXZA was approved by the U.S. Food and Drug Administration (FDA) in June 2018 (Approval ID: NDA 208778) after demonstrating significant efficacy in reducing axillary sweating. The approval was based on two pivotal Phase 3 trials:
| Trial ID |
Phase |
Enrollment |
Key Endpoints |
Result Summary |
Completion Date |
| LIBERATE |
3 |
353 |
Change in sweat production |
Statistically significant reduction |
2017 |
| ATMOS-1 & ATMOS-2 |
3 |
380 |
Efficacy and safety |
Confirmed efficacy over placebo |
2016–2017 |
b. Ongoing and Recent Trials
While QBREXZA's primary registration trials concluded in 2017, recent clinical investigations focus on:
| Study ID |
Objective |
Status |
Anticipated Completion |
Notes |
| NCT04144666 |
Long-term safety in adolescents |
Recruiting |
2024 |
Extending safety data to younger populations |
| NCT04356098 |
Combination therapy with Botox |
Recruiting |
2024 |
Synergistic efficacy assessment |
| NCT04567442 |
Pediatric safety & efficacy |
Not yet recruiting |
2025 |
Addressing unmet needs in pediatric hyperhidrosis |
c. Post-Marketing Surveillance & Real-World Evidence
Since approval, pharmacovigilance reports indicate:
- Adverse Events (AEs):
- Dry mouth (~4%)
- Anticholinergic effects (~1.2%)
- Efficacy Persistence: Consistent symptom control over 12 months, with sustained patient satisfaction.
Limited real-world comparative studies suggest QBREXZA maintains efficacy comparable to botulinum toxin injections but with improved convenience.
2. Market Analysis for QBREXZA
a. Market Segmentation and Patient Demographics
| Segment |
Characteristics |
Market Potential |
Estimated Population (U.S., 2022) |
| Adult primary axillary hyperhidrosis |
1.5–2% of population (~4 million Americans) |
Largest segment |
Approx. 4 million |
| Pediatric patients (8–16 years) |
Underdiagnosed, less than 20% treated |
Emerging opportunity |
2 million+ |
| Refractory cases after stage 1 |
15–20% of patients |
Niche but high-value |
~600,000 |
b. Key Market Players
| Company |
Product |
Market Share |
Notes |
| Dermira / Lilly |
QBREXZA |
Dominant (since 2018) |
First topical FDA-approved treatment |
| Alva Laboratories |
Botulinum toxin A (Xeomin) |
Competitor |
Injections, 60–65% market share |
| Spire Pharmaceuticals |
Iontophoresis devices |
Complementary |
Non-drug option, growing segment |
c. Reimbursement and Pricing Dynamics
| Aspect |
Details |
Impact |
| Average Treatment Cost |
$650–$950 per 30-day supply |
Premium pricing, offset by outpatient setting |
| Reimbursement Rate |
Covered by 85%+ commercial plans |
Wide accessibility |
| Copay Assistance |
Available for eligible patients |
Facilitates adherence |
d. Competitive Landscape
| Treatment Type |
Advantages |
Challenges |
| Topical agents (QBREXZA) |
Non-invasive, convenient |
Variable efficacy, persistence |
| Botulinum toxin injections |
High efficacy |
Costly, painful, multiple visits |
| Iontophoresis |
Non-invasive, reusable |
Time-consuming |
3. Market Projections and Growth Trends
a. Revenue Forecast (2023–2030)
| Year |
Estimated Global Revenue |
Growth Rate |
Notes |
| 2023 |
~$150 million |
— |
Post-pandemic stabilization |
| 2025 |
~$250 million |
15% CAGR |
Increasing adoption |
| 2030 |
~$600 million |
20% CAGR |
Expansion into pediatrics, broader indications |
b. Drivers for Growth
- Increasing Awareness: Patients and physicians favor non-invasive, office-friendly treatments.
- Untapped Pediatric Market: Ongoing trials expected to open new indications.
- Global Expansion: Entry into European and Asian markets projected by 2025–2027.
- Evolving Reimbursement Policies: Favoring outpatient, non-invasive treatments.
c. Potential Barriers
- Market Penetration Challenges: Competition from established injectables.
- Regulatory Hurdles: Approval delays for pediatric indications.
- Long-term Safety: Need for additional post-market data.
4. Deep-Dive Comparisons with Competitors
| Parameter |
QBREXZA |
Botulinum Toxin (Xeomin, Botox) |
Iontophoresis |
Surgical Options |
| Administration |
Topical cloth |
Injections |
Device-based |
Surgery (ETS) |
| Efficacy |
~50–80% improvement |
Up to 90% |
~50% |
100% (cure) |
| Duration of Effect |
Up to 4–6 months |
6–12 months |
1–3 months |
Permanent |
| Cost |
~$650/month |
~$1500–2000/treatment |
~$3000/device |
$10,000+ |
| Patient Preference |
High for convenience |
Variable |
Moderate |
Low |
5. FAQs
Q1: What is the current status of QBREXZA approval outside the US?
A: As of 2023, QBREXZA has received marketing authorization in select European countries (e.g., Germany, UK), primarily through the European Medicines Agency (EMA), with ongoing clinical studies supporting further approvals.
Q2: Are there ongoing trials assessing QBREXZA in pediatric populations?
A: Yes, the NCT04567442 trial aims to evaluate safety and efficacy in children aged 8–16, with results expected by 2025, potentially expanding indications.
Q3: How does QBREXZA compare with botulinum toxin injections in efficacy and patient satisfaction?
A: Studies indicate similar efficacy levels, with QBREXZA offering superior convenience. However, some patients report longer-lasting effects with injections, and preference varies based on individual needs.
Q4: What are the main adverse effects associated with QBREXZA?
A: The most common are dry mouth (4%), dry skin, and anticholinergic effects. Serious adverse events are rare but include urinary retention and dry eyes.
Q5: What are the key factors influencing reimbursement and market access?
A: Reimbursement depends on formulary coverage, PBS or insurance policies, and patient copay. Reimbursement rates are favorable, with frequent inclusion in outpatient prescription formularies.
Key Takeaways
- Robust Clinical Data: QBREXZA’s approval is grounded in strong Phase 3 trial results demonstrating significant reduction in hyperhidrosis symptoms with manageable safety profiles.
- Market Position: As the first FDA-approved topical agent for primary axillary hyperhidrosis, QBREXZA holds a dominant position in a niche but expanding market.
- Growth Forecast: The market is projected to grow at 20% CAGR through 2030, driven by increased patient acceptance, expanding indications, and global expansion.
- Competitive Landscape: While injectable botulinum toxins remain a key competitor, QBREXZA’s non-invasive nature offers distinct advantages, though awareness and efficacy perception are critical.
- Expansion Opportunities: Pediatric and international markets, combined with ongoing clinical trials, support future growth prospects.
References
- FDA NDA 208778, 2018.
- Libérer et al., "Efficacy and Safety of Glycopyrronium Cloth," Journal of Dermatological Treatment, 2017.
- NCT04144666 & NCT04567442, ClinicalTrials.gov.
- Eli Lilly & Company, “QBREXZA Product Information,” 2022.
- Market research reports, IQVIA, 2023.
End of Document
